RxSight和Replimune的投资者可以就据称违反证券法的行为寻求赔偿。 Investors in RxSight and Replimune may seek compensation for alleged securities law violations.

在2024年11月至2025年7月期间蒙受损失的RxSight、Inc.和Replumune Group Inc.的投资者可能有资格根据联邦证券法获得赔偿。 Investors in RxSight, Inc. and Replimune Group, Inc. who suffered losses between November 2024 and July 2025 may be eligible for compensation under federal securities laws. 集体诉讼指控两家公司作虚假陈述并隐瞒问题。 Class action lawsuits allege false statements and concealment of issues by both companies. 投资者应在9月22日主要原告的最后期限之前咨询法律顾问。 Investors should consult legal counsel before the September 22 lead plaintiff deadline. 律师事务所提供免费咨询和应急收费安排。 Law firms are offering free consultation and contingency fee arrangements.